-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] The flow of talents in the pharmaceutical arena has become the norm
.
In 2022, such flows are still appearing to be more frequent
.
A few days ago, AstraZeneca China internal email announced internally: AstraZeneca China Vice President, Head of Cardiovascular, Renal and Metabolism Business Unit Mr.
Zhu Tong decided to leave AstraZeneca China to seek career development opportunities outside
.
It is reported that Zhu Tong's term of office will officially end on April 9, 2022
.
From now on, AstraZeneca China's Cardiovascular, Renal and Metabolism Business Unit, headed by Zhu Tong, will be temporarily led by AstraZeneca China General Manager Lai Minglong
.
Interestingly, AstraZeneca executives have left very frequently in recent years
.
Statistics show that from July 2021 to the present, a total of 9 executives from AstraZeneca China have resigned
.
Among them, many executives joined local innovative pharmaceutical companies after leaving, such as Dong Lijun, Zhang Anwei, Wang Dong joined Luoxin Pharmaceutical, Du Haochen and Yin Min joined BeiGene
.
In addition to AstraZeneca, many multinational pharmaceutical companies have also undergone major personnel adjustments this year: for example, the head of the Novartis Oncology Hematology Division resigned; the position of the head of the Takeda Oncology Division was finally settled after 2 months of vacancy ; Fresenius Kabi China changed its chief financial officer; Abbott's global vice president resigned,
etc.
In this regard, people in the industry generally believe that what is reflected behind this is the transformation pains of enterprises and the escalation of talent competition under the development environment of the pharmaceutical industry
.
At present, in addition to multinational pharmaceutical companies, local pharmaceutical companies are also continuously affected, and executive changes are also very frequent
.
It is understood that on March 11, Heavy Pharmaceutical Holdings also issued the "Announcement on the Resignation of the Chairman and the Appointment of Directors to Act as the Chairman's Responsibilities"
.
The announcement stated that due to personal reasons, Liu Shaoyun applied to resign from the positions of chairman, director, member and convener of the strategic development and investment committee of the board of directors, and member of the nomination committee of the board of directors
.
On the same day, Heavy Pharmaceutical Holdings also issued the "Announcement on the Resignation of Deputy General Manager and Chief Financial Officer and the Appointment of Chief Financial Officer", stating that it received a resignation report from Zhang Hong, deputy general manager and chief financial officer
.
It is worth noting that in addition to the above pharmaceutical companies, incomplete statistics show that in China, nearly 120 executives from nearly 100 pharmaceutical companies have left since the beginning of 2022, and there are many chairman, general managers, and deputy general managers.
, president, vice president, core technical personnel and other positions
.
Among them, at least 68 resignations occurred in 49 listed pharmaceutical companies
.
On the whole, traditional Chinese medicine companies account for a large proportion, and 19 companies are involved in resignation, followed by chemical pharmaceutical companies, and 6 companies have resigned
.
Most of the reasons were "personal reasons", which accounted for half of the reasons for quitting
.
In general, industry analysts believe that under the background of the continuous advancement of the medical reform policy in the future, it is foreseeable that the strategic adjustment of enterprises will become more frequent, and the accompanying personnel turmoil may continue
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
In 2022, such flows are still appearing to be more frequent
.
A few days ago, AstraZeneca China internal email announced internally: AstraZeneca China Vice President, Head of Cardiovascular, Renal and Metabolism Business Unit Mr.
Zhu Tong decided to leave AstraZeneca China to seek career development opportunities outside
.
It is reported that Zhu Tong's term of office will officially end on April 9, 2022
.
From now on, AstraZeneca China's Cardiovascular, Renal and Metabolism Business Unit, headed by Zhu Tong, will be temporarily led by AstraZeneca China General Manager Lai Minglong
.
Interestingly, AstraZeneca executives have left very frequently in recent years
.
Statistics show that from July 2021 to the present, a total of 9 executives from AstraZeneca China have resigned
.
Among them, many executives joined local innovative pharmaceutical companies after leaving, such as Dong Lijun, Zhang Anwei, Wang Dong joined Luoxin Pharmaceutical, Du Haochen and Yin Min joined BeiGene
.
In addition to AstraZeneca, many multinational pharmaceutical companies have also undergone major personnel adjustments this year: for example, the head of the Novartis Oncology Hematology Division resigned; the position of the head of the Takeda Oncology Division was finally settled after 2 months of vacancy ; Fresenius Kabi China changed its chief financial officer; Abbott's global vice president resigned,
etc.
In this regard, people in the industry generally believe that what is reflected behind this is the transformation pains of enterprises and the escalation of talent competition under the development environment of the pharmaceutical industry
.
At present, in addition to multinational pharmaceutical companies, local pharmaceutical companies are also continuously affected, and executive changes are also very frequent
.
It is understood that on March 11, Heavy Pharmaceutical Holdings also issued the "Announcement on the Resignation of the Chairman and the Appointment of Directors to Act as the Chairman's Responsibilities"
.
The announcement stated that due to personal reasons, Liu Shaoyun applied to resign from the positions of chairman, director, member and convener of the strategic development and investment committee of the board of directors, and member of the nomination committee of the board of directors
.
On the same day, Heavy Pharmaceutical Holdings also issued the "Announcement on the Resignation of Deputy General Manager and Chief Financial Officer and the Appointment of Chief Financial Officer", stating that it received a resignation report from Zhang Hong, deputy general manager and chief financial officer
.
It is worth noting that in addition to the above pharmaceutical companies, incomplete statistics show that in China, nearly 120 executives from nearly 100 pharmaceutical companies have left since the beginning of 2022, and there are many chairman, general managers, and deputy general managers.
, president, vice president, core technical personnel and other positions
.
Among them, at least 68 resignations occurred in 49 listed pharmaceutical companies
.
On the whole, traditional Chinese medicine companies account for a large proportion, and 19 companies are involved in resignation, followed by chemical pharmaceutical companies, and 6 companies have resigned
.
Most of the reasons were "personal reasons", which accounted for half of the reasons for quitting
.
In general, industry analysts believe that under the background of the continuous advancement of the medical reform policy in the future, it is foreseeable that the strategic adjustment of enterprises will become more frequent, and the accompanying personnel turmoil may continue
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
